Advertisement

Heart Failure Reviews

, Volume 23, Issue 4, pp 517–525 | Cite as

Novel drugs for heart rate control in heart failure

  • Agata Bielecka-Dabrowa
  • Stephan von Haehling
  • Jacek Rysz
  • Maciej Banach
Article

Abstract

In patients with heart failure, increased sympathetic activity is associated with a positive chronotropic stimulation leading to accelerated resting heart rate. Elevated heart rate (HR) is a risk factor for cardiovascular events, both in the general population and in patients with heart failure. Ivabradine is a pure HR-lowering agent, and it does not affect myocardial contractility, blood pressure, intracardiac conduction, or ventricular repolarization. In clinical trials such as BEAUTIFUL, CARVIVA HF, SHIFT, and INTENSIFY in patients with systolic left ventricular dysfunction, heart rate reduction with ivabradine brought positive outcomes. However, the results of the recent meta-analysis are rather neutral. In a diabetes mouse model of heart failure with preserved ejection fraction (HFpEF), selective heart rate reduction by If inhibition improved vascular stiffness, left ventricular (LV) contractility, and diastolic function. However, EDIFY (Effect of ivabradine in patients with heart rate with preserved ejection fraction) trial show that the use of ivabradine in patients with HFpEF is not supported. The further clinical trials investigating the use of ivabradine in heart failure should be carried out.

Keywords

Heart failure Ivabradine Heart rate 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Katsi V, Georgiopoulos G, Laina A et al (2017) Left ventricular ejection fraction as therapeutic target: is it the ideal marker? Heart Fail Rev.  https://doi.org/10.1007/s10741-017-9624-5
  2. 2.
  3. 3.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members, Document Reviewers (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891–975CrossRefPubMedGoogle Scholar
  4. 4.
    Franke J, Wolter JS, Meme L, Keppler J, Tschierschke R, Katus HA, Zugck C (2013) Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? Clin Res Cardiol 102(1):23–31CrossRefPubMedGoogle Scholar
  5. 5.
    Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, Reil JC, Swedberg K, Tavazzi L (2013) Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 102(1):11–22CrossRefPubMedGoogle Scholar
  6. 6.
    Zhang GQ, Zhang W (2009) Heart rate, lifespan, and mortality risk. Ageing Res Rev 8:52–60CrossRefPubMedGoogle Scholar
  7. 7.
    Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD (1995) Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26:1257–1263CrossRefPubMedGoogle Scholar
  8. 8.
    Singh BN (2003) Increased heart rate as a risk factor for cardiovascular disease. Eur Heart J Suppl 5:G3–G9CrossRefGoogle Scholar
  9. 9.
    Magder SA (2012) The ups and downs of heart rate. Crit Care Med 40:239–245CrossRefPubMedGoogle Scholar
  10. 10.
    Koeppen BM, Stanton BA (2010) Berne & Levy physiology. Mosby Elsevier, MissouriGoogle Scholar
  11. 11.
    Chaudhary R, Garg J, Krishnamoorthy P, Shah N, Lanier G, Martinez MW, Freudenberger R (2016) Ivabradine: heart failure and beyond. J Cardiovasc Pharmacol Ther 21:335–343CrossRefPubMedGoogle Scholar
  12. 12.
    Vitale C, Iellamo F, Volterrani M, Lombardi M, Fini M, Banach M, Rosano GM (2010) Heart rate control in an unselected consecutive population of outpatients with stable coronary artery disease: analysis of the CARDIf Study Cohort. Angiology 61(8):763–767CrossRefPubMedGoogle Scholar
  13. 13.
    Swedberg K, Komajda M (2012) The beat goes on: on the importance of heart rate in chronic heart failure. Eur Heart J 233:1044–1045CrossRefGoogle Scholar
  14. 14.
    Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Böhm M (2011) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100:11–19CrossRefPubMedGoogle Scholar
  15. 15.
    Katz AM (1990) Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N Engl J Med 322:100–110CrossRefPubMedGoogle Scholar
  16. 16.
    Bielecka-Dabrowa A, von Haehling S, Aronow WS, Ahmed MI, Rysz J, Banach M (2013) Heart failure biomarkers in patients with dilated cardiomyopathy. Int J Cardiol 168(3):2404–2410CrossRefPubMedGoogle Scholar
  17. 17.
    Gupta S, Figueredo VM (2014) Tachycardiamediatedcardiomyopathy: pathophysiology, mechanisms, clinical features and management. Int J Cardiol 172(1):40–46CrossRefPubMedGoogle Scholar
  18. 18.
    Anker MS, Ebner N, Hildebrandt B, Springer J, Sinn M, Riess H, Anker SD, Landmesser U, Haverkamp W, von Haehling S (2016) Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study. Eur J Heart Fail 18(12):1524–1534CrossRefPubMedGoogle Scholar
  19. 19.
    Teodorescu C, Reinier K, Uy-Evanado A, Gunson K, Jui J, Chugh SS (2013) Resting heart rate and risk of sudden cardiac death in the general population: influence of left ventricular systolic dysfunction and heart rate-modulating drugs. Heart Rhythm 10(8):1153–1158CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL investigators (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372(9641):817–821CrossRefPubMedGoogle Scholar
  21. 21.
    Logeart D, Seronde MF, Degroote P et al (2012) Raised heart rate at dis charge after acute heart failure is an independent predictor of one-year mortality [abstract P2775]. Eur Heart J 33(suppl):485Google Scholar
  22. 22.
    Gillman MW, Kannel WB, Belanger A, D’Agostino RB (1993) Influence of heart rate on mortality among persons with hypertension: the Framingham study. Am Heart J 125:1148–1154CrossRefPubMedGoogle Scholar
  23. 23.
    Chang M, Havlik RJ, Corti MC, Chaves PH, Fried LP, Guralnik JM (2003) Relation of heart rate at rest and mortality in the Women’s Health and Aging Study. Am J Cardiol 92:1294–1299CrossRefPubMedGoogle Scholar
  24. 24.
    Kristal-Boneh E, Silber H, Harari G, Froom P (2000) The association of resting heart rate with cardiovascular, cancer and allcause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 21:116–124CrossRefPubMedGoogle Scholar
  25. 25.
    Fujita B, Franz M, Goebel B, Fritzenwanger M, Figulla HR, Kuethe F, Ferrari M, Jung C (2012) Prognostic relevance of heart rate at rest for survival and the quality of life in patients with dilated cardiomyopathy. Clin Res Cardiol 101:701–707CrossRefPubMedGoogle Scholar
  26. 26.
    Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, de Leeuw PW, Jaaskivi M, Leonetti G, Nachev C, O'Brien ET, Parati G, Rodicio JL, Roman E, Sarti C, Tuomilehto J, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators (2002) Systolic Hypertension in Europe (Syst-Eur) Trial Investigators (2002) Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 162:2313–2321CrossRefPubMedGoogle Scholar
  27. 27.
    Palatini P, Casiglia E, Julius S, Pessina AC (1999) High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 159:585–592CrossRefPubMedGoogle Scholar
  28. 28.
    McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150:784–794CrossRefPubMedGoogle Scholar
  29. 29.
    Pourdjabbar A, Dwivedi G, Haddad R, Saikali A, Mielniczuk L, Haddad H (2015) Heart rate control in patients with left ventricular systolic dysfunction and heart failure. Int J Cardiol 184:276–277CrossRefPubMedGoogle Scholar
  30. 30.
    Fu M, Ahrenmark U, Berglund S, All investigators of the HR-HF study et al (2017) Adherence to optimal heart rate control in heart failure with reduced ejection fraction: insight from a survey of heart rate in heart failure in Sweden (HR-HF study). Clin Res Cardiol 106:960–973.  https://doi.org/10.1007/s00392-017-1146-6 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Swedberg K, Komajda M, Böhm BJ, Robertson M, Tavazzi L, Ford I (2012) For the SHIFT investigators effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Findings from the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study. J Am Coll Cardiol 59(22):1938–1945CrossRefPubMedGoogle Scholar
  32. 32.
    Sartiani L, Mannaioni G, Masi A, Novella Romanelli M, Cerbai E (2017) The hyperpolarization-activated cyclic nucleotide-gated channels: from biophysics to pharmacology of a unique family of ion channels. Pharmacol Rev 69(4):354–395CrossRefPubMedGoogle Scholar
  33. 33.
    Verkek AO (2009) Pacemaker activity of the human sinoatrial node: role of the hyperpolarization-activated current, If. Int JCardiol 132:318–336CrossRefGoogle Scholar
  34. 34.
    Di Francesco D (2007) The funny current. Cellular basis for the control of heart rate. Drugs 67(Suppl 2):15–24CrossRefGoogle Scholar
  35. 35.
    Di Francesco D (1991) Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature 351:145–147CrossRefGoogle Scholar
  36. 36.
    Camm AJ, Lau CP (2003) Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D 4:83–89CrossRefPubMedGoogle Scholar
  37. 37.
    Manz M, Reuter M, Lauck G, Omran H, Jung W (2003) A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100:149–155CrossRefPubMedGoogle Scholar
  38. 38.
    Ferrari R (2014) Ivabradine: heart rate and left ventricular function. Cardiology 128:226–230CrossRefPubMedGoogle Scholar
  39. 39.
    Vilaine JP (2006) The discovery of the selective If current inhibitor ivabradine. A new therapeutic approach to ischemic disease. Pharmacol Res 53:424–434CrossRefPubMedGoogle Scholar
  40. 40.
    Bucchi A, Barbuti A, Baruscotti M, DiFrancesco D (2007) (220) Heart rate reduction via selective ‘funny’ channel blockers. Curr Opin Pharmacol 7:208–213CrossRefPubMedGoogle Scholar
  41. 41.
    Nakada N (2016) Investigation of metabolite profile of YM758, a novel If channel inhibitor. Drugs R D 16(2):205CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Umehara KI, Nakamata T, Suzuki K, Noguchi K, Usui T, Kamimura H (2008) Pharmacokinetics of YK754, a novel If channel inhibitor in rats, dogs and humans. Eur J Drug Metab Pharmacokinet 33:117–127CrossRefPubMedGoogle Scholar
  43. 43.
    Owczarek J, Jasińska M, Drożdż J, Orszulak-Michalak D (2012) Concomitant administration of simvastatin with ivabradine in contrast to metoprolol intensifies slowing of heart rate in normo- and hypercholesterolemic rats. Arch Med Sci 8(3):549–554CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Tardiff JC (2005) Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26:2529–2536CrossRefGoogle Scholar
  45. 45.
    Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double blind, placebo-controlled trial. Lancet 372:807–816CrossRefPubMedGoogle Scholar
  46. 46.
    Borer JS, Deedwania PC, Kim JB, Böhm M (2016) Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. Am J Cardiol 118(12):1948–1953CrossRefPubMedGoogle Scholar
  47. 47.
    Werdan K, Ebelt H, Nuding S, Höpfner F, Hack G, Müller-Werdan U (2012) Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol 101:365–373CrossRefPubMedGoogle Scholar
  48. 48.
    Koester R, Kaehler J, Meinertz T (2011) Ivabradine for the treatment of stable angina pectoris in octogenarians. Clin Res Cardiol 100:121–128CrossRefPubMedGoogle Scholar
  49. 49.
    Koester R, Kaehler J, Ebelt H, Soeffker G, Werdan K, Meinertz T (2010) Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin Res Cardiol 99:665–672CrossRefPubMedGoogle Scholar
  50. 50.
    M V, Cice G, Caminiti G et al (2011) Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). Int J Cardiol 151(2):218–224CrossRefGoogle Scholar
  51. 51.
    Swedberg K, Komajda M, Böhm M, SHIFT Investigators et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875–885CrossRefPubMedGoogle Scholar
  52. 52.
    Tardif JC, O’Meara E, Komajda M et al (2011) Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 32:2507–2515CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Fang Y, Debunne M, Vercauteren M, Brakenhielm E, Richard V, Lallemand F, Henry JP, Mulder P, Thuillez C (2012) Heart rate reduction induced by the If current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia. J Cardiovasc Pharmacol 59:260–267CrossRefPubMedGoogle Scholar
  54. 54.
    Reil JCH, Tardif JC, Ford I et al (2013) Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 62:1977–1985CrossRefPubMedGoogle Scholar
  55. 55.
    Mert KU, Dural M, Mert GÖ, Iskenderov K, Özen A (2017) Effects of heart rate reduction with ivabradine on the international ındex of erectile function (IIEF-5) in patients with heart failure. Aging Male 26:1–6Google Scholar
  56. 56.
    Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pfeffer MA, McMurray J, Solomon SD, CHARM Investigators (2012) Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) program. J Am Coll Cardiol 59:1785–1795CrossRefPubMedGoogle Scholar
  57. 57.
    Busseuil D, Shi Y, Mecteau M, Brand G, Gillis MA, Thorin E, Asselin C, Roméo P, Leung TK, Latour JG, Des Rosiers C, Bouly M, Rhéaume E, Tardif JC (2010) Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology 117:234–242CrossRefPubMedGoogle Scholar
  58. 58.
    Fischer-Rasokat U, Honold J, Lochmann D, Wolter S, Liebetrau C, Fichtlscherer S, Möllmann H, Spyridopoulos I, Hamm CW (2016) Beta-blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index. Clin Res Cardiol 105:527–534CrossRefPubMedGoogle Scholar
  59. 59.
    Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH (2013) Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 62:1330–1338CrossRefPubMedGoogle Scholar
  60. 60.
    Pal N, Sivaswamy N, Mahmod M et al (2015) Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation 132:1719–1725CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P, Voors AA, Dominjon F, Henon-Goburdhun C, Pannaux M, Böhm M, prEserveD left ventricular ejectIon fraction chronic heart Failure with ivabradinestudY (EDIFY) Investigators (2017) Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail 19:1495–1503.  https://doi.org/10.1002/ejhf.876 CrossRefPubMedGoogle Scholar
  62. 62.
    Sisakian H, Sargsyan T, Khachatryan A (2016) Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiol 71:317–322CrossRefPubMedGoogle Scholar
  63. 63.
    Rodrigues PG, Leite-Moreira AF, Falcao-Pires I (2016) Myocardial reverse remodeling: how far can we rewind? Am J Physiol Heart Circ Physiol 310:1402–1422CrossRefGoogle Scholar
  64. 64.
    Kang S, Li CJ, Zhang XM (2017) Ivabradine has a neutral effect on mortality in randomized controlled trials. Medicine (Baltimore) 96(40):e8067.  https://doi.org/10.1097/MD.0000000000008067 CrossRefGoogle Scholar
  65. 65.
    Tanboğa İH, Topçu S, Aksakal E et al (2016) The risk of atrial fibrillation with ivabradine treatment: a meta-analysis with trial sequential analysis of more than 40000 patients. Clin Cardiol 39(10):615–620CrossRefPubMedGoogle Scholar
  66. 66.
    Martin RI, Pogoryelova O, Koref MS et al (2014) Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart 100(19):1506–1510CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Hennen R, Friedrich I, Hoyer D, Nuding S, Rauchaus M, Shulze M, Schlisske S, Schwesig R, Schlitt A, Buerke M, Muller-Werdan U, Werdan K, Schmidt H (2008) Autonomic dysfunction and beta-adrenergic blockers in multiple organ dysfunction syndrome. Dtsch Med Wochenschr 133:2500–2504CrossRefPubMedGoogle Scholar
  68. 68.
    Morelli A (2011) Strict heart rate control with esmolol in septic shock: a randomized, controlled, Clinical Pilot Study NCT01231698
  69. 69.
    Tarnow J, Komar K (1988) Altered hemodynamic response to dobutamine in relation to the degree of preoperative beta-adrenoceptor blockade. Anesthesiology 68:912–919CrossRefPubMedGoogle Scholar
  70. 70.
    Borer JS (2004) Drug insight: If inhibitors as specific heart-rate reducing agents. Nat Clin Pract Cardiovasc Med 1:103–109CrossRefPubMedGoogle Scholar
  71. 71.
    Hoke RS, Müller-Werdan U, Lautenschläger C, Werdan K, Ebelt H (2012) Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study. Clin Res Cardiol 101:139–147CrossRefPubMedGoogle Scholar
  72. 72.
    Nuding S, Schröder J, Presek P et al (2017) Heart rates in patients with multiple organ dysfunction syndrome with the If (funny channel current) inhibitor ivabradine. Shock.  https://doi.org/10.1097/SHK.0000000000000992
  73. 73.
    Reil JC, Hohl M, Reil GH, Granzier HL, Kratz MT, Kazakov A, Fries P, Müller A, Lenski M, Custodis F, Gräber S, Fröhlig G, Steendijk P, Neuberger HR, Böhm M (2013) Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J 34:2839–2849CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Agata Bielecka-Dabrowa
    • 1
  • Stephan von Haehling
    • 2
  • Jacek Rysz
    • 3
  • Maciej Banach
    • 1
  1. 1.Department of Hypertension, Chair of Nephrology and HypertensionMedical University of LodzLodzPoland
  2. 2.Department of Cardiology and PneumologyUniversity of Göttingen Medical CenterGöttingenGermany
  3. 3.Department of Nephrology, Hypertension and Family Medicine, Chair of Nephrology and HypertensionMedical University of LodzLodzPoland

Personalised recommendations